References
- The National Board of Health and Welfare. Cancer incidence in Sweden 1999. Stockholm: The National Board of Health and Welfare, 2001.
- Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreatic cancer. Ann Oncol 1996; 7: 347–53.
- Williamson RCN. Pancreatic cancer: the greatest oncological challenge. Br Med J 1991; 296: 445.
- Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin North Am 1998; 7: 67.
- Evans D, Abbruzzese J, Willert C. Cancer of the pancreas. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer: practice of oncology, 6th ed. Philadelphia: Lippincott-Raven, 2001: p. 1126–61.
- Södra sjukvardsregionen. Treatment guidelines for pancreatic cancer 1999 (in Swedish) Vardprogram f6r pankreascancer 1999. Lund: Onkologiskt Centrum, Södra sjukvardsregionen; 1999. Available from http://www.ocsyd.lu.seNardprog/pan-creas.pdf.
- Södra Regionvärdsnämnden. Regional prices and reimburse-ments for the Southern Sweden Hospital Region 2001 (in Swedish) Regionala priser och ersättningar 2001 f6r s6dra sjukvardsregionen. Lund: S6dra Regionvardsnämnden, 2000.
- FASS -pharmaceuticals in Sweden 2001 (in Swedish) FASS - läkemedel i Sverige 2001. Stockholm: LINFO; 2001.
- Landstingsförbundet. Available from http://www.lEse/nyheter/ download/sjukre98.xls.
- Permert J, Hafström L, Nygren P, et al. A systematic overview of chemotherapy effects in pancreatic cancer. Acta Oncol 2001; 40: 361–70.
- Holbrook RF, Hargrave K, Traverso W. A prospective cost analysis of pancreatoduodenectomy. Am J Surg 1996; 171: 508–11.
- Raikar GV, Melin MM, Lettieri SZ, et al. Cost-effective analysis of surgical palliation versus endoscopic stenting in the management of unresectable pancreatic cancer. Ann Surg Oncology 1996; 3: 470–5.
- Ragnarson-Tennvall G, Wilking N. Treatment of locally advanced Pancreatic carcinoma in Sweden. A health economic comparison of palliative treatment with best supportive care versus palliative treatment with gemcitabine in combination with best supportive care. Pharmacoeconomics 1999; 15: 377–84.
- Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267–74.
- Wilson LS, Lightwood JM. Pancreatic cancer: total costs and utilisation of health services. J Surg Oncol 1999; 71: 171–81.
- Du W, Touchette D, Vaitkevicius VK, et al. Cost analysis of pancreatic carcinoma treatment. Cancer 2000; 89: 1917–24.
- Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER-Medicare data, Med Care 2002; 40: 8 Suppl: 104–117.
- Tennvall G, Karlsson G. Cancer treatment in Sweden-costs of drugs, inpatient and outpatient care from 1985 to 1996 and cost effectiveness of new drugs. Acta Oncol 1998; 37: 447–53.
- Houle C, Will BP, Bertelot JM, Evans WK. Use of POHEM to estimate direct medical costs of current practice and new treatments associated with lung cancer in Canada. Analytic Studies Branch Research Papers Series No. 99. Statistics Canada, 1997.